Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EDP-297 in Healthy Subjects
NCT04559126Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP-297 in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety measured by adverse events. Started Sep 2020; status: completed.
02
Drugs
EDP-297
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04559126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559126.